In which clinical situations are beta‑blockers appropriate for treating hypertension, and what are their other major indications such as heart failure, chronic coronary syndrome, and arrhythmias?

Beta-Blocker Indications: A Structured Clinical Framework

Beta-blockers are NOT first-line therapy for uncomplicated hypertension, but they become preferred agents when specific comorbidities exist—particularly cardiac conditions where they reduce mortality and morbidity. 1

Understanding the Hierarchy: When Beta-Blockers Move to First-Line

For Hypertension Alone

• Uncomplicated hypertension: Beta-blockers are generally NOT first-line; ACE inhibitors, ARBs, non-dihydropyridine calcium channel blockers, and thiazides remain preferred 1
• Exception—younger patients with hyperkinetic circulation: Beta-blockers are appropriate first-line when resting heart rate >80 bpm, as elevated heart rate independently predicts cardiovascular events and reflects sympathetic overactivity 1, 2
• Exception—younger/middle-aged hypertensives (<60 years): Beta-blockers reduce myocardial infarction by 35-50% and stroke by 50-55% versus placebo in this population, making them reasonable first-line choices 3

Compelling Cardiac Indications (Beta-Blockers Become First-Line)

Post-myocardial infarction: Mandatory therapy to reduce mortality 1

Chronic coronary syndrome/stable angina:

• First-line anti-ischemic therapy alongside dihydropyridine calcium channel blockers 4
• Reduce myocardial oxygen consumption by decreasing heart rate and contractility 4
• Particularly indicated when angina coexists with high heart rate or hypertension 4

Heart failure with reduced ejection fraction (HFrEF):

• Cornerstone of guideline-directed medical therapy (GDMT) 1
• Early initiation recommended as first-line medication 5
• Caution: In severe acute decompensated heart failure or cardiogenic shock, beta-blocker initiation can be hazardous; requires careful titration 5

Heart failure with preserved ejection fraction (HFpEF):

• The SENIORS trial showed benefit in composite endpoints (hospitalization and death) regardless of ejection fraction 1
• Up to 96% of HFpEF trial participants receive beta-blockers as add-on therapy 1

Arrhythmias:

• Atrial fibrillation: For rate control 1, 6
• Ventricular arrhythmias: Particularly in hypertensive patients with left ventricular hypertrophy (LVH), where beta-blockers reduce sudden cardiac death risk 6
• Supraventricular tachyarrhythmias: Primary therapy 7

Other cardiac conditions:

• Aortic dissection 1
• Obstructive cardiomyopathy 8

Additional Clinical Scenarios Favoring Beta-Blockers

Pregnancy/childbearing potential: Alternative to ACE inhibitors/ARBs in younger hypertensive women 1

Conditions with sympathetic overactivity:

• Thyrotoxicosis 7
• Essential tremor 8, 7
• Migraine prophylaxis 8, 7
• Anxiety with hyperkinetic circulation (palpitations, tachycardia) 8

Perioperative hypertension: Particularly in vascular surgery patients with known ischemic heart disease 8

Diabetes mellitus: Contrary to older teaching, beta-blockers are appropriate; atenolol was as effective as ACE inhibition in the UKPDS study for obese hypertensive diabetics 3

Critical Pathophysiologic Rationale

Sympathetic nervous system activation occurs throughout the hypertension disease spectrum—from early to late phases—and extends to related conditions (heart failure, ischemic heart disease, obesity, obstructive sleep apnea) 1. This makes beta-blockers pathophysiologically appropriate beyond their blood pressure-lowering effects 1.

High plasma norepinephrine levels independently predict cardiovascular events and death in younger hypertensive patients, regardless of blood pressure control 3. This explains why agents that increase sympathetic activity (diuretics, dihydropyridine calcium blockers, ARBs) may be inappropriate first-line choices in younger patients 3.

Common Pitfalls to Avoid

Not all beta-blockers are equivalent: Atenolol should NOT be used as an antihypertensive drug due to inferior outcomes 7. Newer vasodilating beta-blockers (carvedilol, nebivolol) have more favorable hemodynamic and metabolic profiles 7, 9

Former "contraindications" are outdated: Beta-blockers are now proven safe and beneficial in COPD and peripheral artery disease, conditions where they were previously restricted 1

Avoid in specific structural heart disease contexts: Do not use sotalol in LVH patients; avoid diltiazem and verapamil (not beta-blockers, but relevant) in HFrEF 6

Heart rate and blood pressure thresholds matter: Beta-blockers are not suitable when resting heart rate <50 bpm (unless pacemaker support available) or in severe hypotension 4

Practical Algorithm for Decision-Making

1. Does the patient have post-MI, HFrEF, chronic coronary syndrome, or significant arrhythmias? → Beta-blocker is mandatory/first-line 1, 4

2. Is the patient hypertensive with resting heart rate >80 bpm? → Beta-blocker is preferred first-line 1, 2

3. Is the patient <60 years old with uncomplicated hypertension? → Beta-blocker is reasonable first-line (especially in men, non-smokers) 3

4. Is the patient >60 years old with uncomplicated hypertension and no cardiac comorbidities? → Prefer ACE/ARB/CCB/thiazide; reserve beta-blockers for add-on therapy 1

5. Does the patient have multiple comorbidities (diabetes, obesity, sleep apnea)? → Consider beta-blocker given sympathetic overactivity in these conditions 1

The 2022 ESC/ESH guidelines emphasize that blood pressure reduction magnitude matters more than the specific drug class for cardiovascular protection, but beta-blockers excel when comorbidities align with their specific benefits 1. The 2023 ESH guidelines have restored beta-blockers to equal standing among the five main antihypertensive classes, recognizing their versatility beyond compelling indications 2.